Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Unicycive Therapeutics, Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +2 vs. Q1 2023
- Shares held
- 1.07M
- −612.0K (−36.3%) vs. Q1 2023
- Total value
- $1.38M
- −$2.17M (−61.2%) vs. Q1 2023
- New holders
- 5
- 2 more added
- Sold out
- 3
- 2 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting UNCY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 79 | $54.6M |
| Q1 2026 | 51 | $65.2M |
| Q4 2025 | 35 | $47.5M |
| Q3 2025 | 30 | $27.4M |
| Q2 2025 | 20 | $24.6M |
| Q1 2025 | 29 | $34.5M |
| Q4 2024 | 31 | $49.0M |
| Q3 2024 | 29 | $19.1M |
| Q2 2024 | 24 | $9.52M |
| Q1 2024 | 23 | $31.6M |
| Q4 2023 | 16 | $11.3M |
| Q3 2023 | 16 | $12.2M |
| Q2 2023 | 15 | $1.38M |
| Q1 2023 | 13 | $3.54M |
| Q4 2022 | 9 | $428.3K |
| Q3 2022 | 12 | $571.0K |
| Q2 2022 | 15 | $992.0K |
| Q1 2022 | 12 | $1.48M |
| Q4 2021 | 12 | $2.30M |
| Q3 2021 | 10 | $3.02M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Unicycive Therapeutics, Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 647,416 | $828.7K | 0.10% | 00.0% | Unchanged |
| Vanguard Group Inc | 115,057 | $147.3K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 95,931 | $122.8K | 0.00% | +95,931 | New |
| Geode Capital Management, LLC | 66,752 | $85.4K | 0.00% | −29,146−30.4% | Reduced |
| State Street Corp | 35,036 | $44.8K | 0.00% | 00.0% | Unchanged |
| Ground Swell Capital, LLC | 20,001 | $25.6K | 0.06% | +20,001 | New |
| Captrust Financial Advisors | 18,800 | $24.1K | 0.00% | 00.0% | Unchanged |
| Tandem Capital Management Corp | 15,500 | $19.8K | 0.01% | 00.0% | Unchanged |
| Two Sigma Advisers, LP | 15,200 | $19.5K | 0.00% | +600+4.1% | Added |
| Centiva Capital, LP | 15,186 | $19.4K | 0.00% | +15,186 | New |
| XTX Topco Ltd | 14,461 | $18.5K | 0.00% | +14,461 | New |
| Oxbow Advisors, LLC | 11,861 | $15.2K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,067 | $2.65K | 0.00% | −1,352−39.5% | Reduced |
| UBS Group AG | 1,169 | $1.50K | 0.00% | +1,169 | New |
| Wells Fargo & Company | 49 | $63 | 0.00% | +2+4.3% | Added |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −717,349−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −11,459−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −1−100.0% | Sold out |